Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma

Nature

Volumn 534, Issue 7607, 2016, Pages 407-411

  Fox, Raymond G ^a,b,c   Lytle, Nikki K ^a,b,c   Jaquish, Dawn V ^c,d   Park, Frederick D ^a,b,c,e   Ito, Takahiro ^a,b,c   Bajaj, Jeevisha ^a,b,c   Koechlein, Claire S ^a,b,c   Zimdahl, Bryan ^a,b,c   Yano, Masato ^f,l   Kopp, Janel L ^b,g   Kritzik, Marcie ^a,b,c   Sicklick, Jason K ^c,d   Sander, Maike ^b,g   Grandgenett, Paul M ^h   Hollingsworth, Michael A ^f   Shibata, Shinsuke ⁱ   Pizzo, Donald ⁱ   Valasek, Mark A ^a   Sasik, Roman ^j   Scadeng, Miriam ^f   Okano, Hideyuki ^k   Kim, Youngsoo ^k   Macleod, A Robert ^c,d   Lowy, Andrew M ^c,d   Reya, Tannishtha ^a,b,c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ISIS PHARMACEUTICALS   (United States)

^l NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CRIZOTINIB; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; K RAS PROTEIN; MUSASHI 1 PROTEIN; MUSASHI 2 PROTEIN; MUSASHI PROTEIN; PROTEIN P53; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; SMAD4 PROTEIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; MSI1 PROTEIN, HUMAN; MSI1H PROTEIN, MOUSE; MSI2H PROTEIN, MOUSE; NERVE PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; DETECTION METHOD; DISEASE; DRUG; GENOME; LESION; STEM; TUMOR;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL SURVIVAL; CIRCULATING TUMOR CELL; COLONY FORMATION; CONTROLLED STUDY; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LOXP SITE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; MOLECULAR IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; REPORTER GENE; SURVIVAL RATE; TUMOR EMBOLISM;

MUS;

ANIMALS; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DELETION; GENES, REPORTER; HUMANS; MALE; MICE; MODELS, GENETIC; MOLECULAR IMAGING; NEOPLASTIC CELLS, CIRCULATING; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976328190     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17988     Document Type: Article

References (48)

1. Yachida, S. & Iacobuzio-Donahue, C. A. The pathology and genetics of metastatic pancreatic cancer. Arch. Pathol. Lab. Med. 133, 413-422 (2009).
2. Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554 (1988).
3. Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996).
4. Redston, M. S. et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54, 3025-3033 (1994).
5. Nakamura, M., Okano, H., Blendy, J. A. & Montell, C. Musashi, a neural RNA-binding protein required for Drosophila adult external sensory organ development. Neuron 13, 67-81 (1994).
6. Okano, H., Imai, T. & Okabe, M. Musashi: A translational regulator of cell fate. J. Cell Sci. 115, 1355-1359 (2002).
7. Sakakibara, S. et al. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc. Natl Acad. Sci. USA 99, 15194-15199 (2002).
8. Hope, K. J. et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell 7, 101-113 (2010).
9. Ito, T. et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466, 765-768 (2010).
10. Kharas, M. G. et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature Med. 16, 903-908 (2010).
11. Kwon, H. Y. et al. Tetraspanin 3 is required for the development and propagation of acute myelogenous leukemia. Cell Stem Cell 17, 152-164 (2015).
12. de Andrés-Aguayo, L. et al. Musashi 2 is a regulator of the HSC compartment identified by a retroviral insertion screen and knockout mice. Blood 118, 554-564 (2011).
13. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
14. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nature Genet. 32, 128-134 (2002).
15. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
16. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
17. Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494-501 (2005).
18. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
19. Kim, M. P. et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 6, e20636 (2011).
20. Dosch, J. S., Ziemke, E. K., Shettigar, A., Rehemtulla, A. & Sebolt-Leopold, J. S. Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer. Cancer Res. 75, 4582-4592 (2015).
21. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
22. Li, C. et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141, 2218-2227 (2011).
23. Belkina, A. C. & Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer. Nature Rev. Cancer 12, 465-477 (2012).
24. Cleynen, I. & Van de Ven, W. J. The HMGA proteins: A myriad of functions (review). Int. J. Oncol. 32, 289-305 (2008).
25. Hung, G. et al. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 23, 369-378 (2013).
26. Seth, P. P. et al. Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13 (2009).
27. Li, N., Li, Q., Tian, X. Q., Qian, H. Y. & Yang, Y. J. Mipomersen is a promising therapy in the management of hypercholesterolemia: A meta-Analysis of randomized controlled trials. Am. J. Cardiovasc. Drugs 14, 367-376 (2014).
28. Hong, D. et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Transl. Med. 7, 314ra185 (2015).
29. Lee, R. G., Crosby, J., Baker, B. F., Graham, M. J. & Crooke, R. M. Antisense technology: An emerging platform for cardiovascular disease therapeutics. J. Cardiovasc. Transl. Res. 6, 969-980 (2013).
30. Saad, F. et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17, 5765-5773 (2011).
31. Koechlein, C.S. et al. High resolution imaging and computational analysis of hematopoietic cell dynamics in vivo. Nature Comm. (in the press).
32. Domen, J., Cheshier, S. H. & Weissman, I. L. The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J. Exp. Med. 191, 253-264 (2000).
33. Rovira, M. et al. Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc. Natl Acad. Sci. USA 107, 75-80 (2010).
34. R Development Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, 2012).
35. Wu, J. et al. gcrma: background adjustment using sequence information. R package version 2.37.0.
36. Sásik, R., Woelk, C. H. & Corbeil, J. Microarray truths and consequences. J. Mol. Endocrinol. 33, 1-9 (2004).
37. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
38. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
39. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
40. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
41. Efron, B. Microarrays, empirical Bayes and the two-groups model. Stat. Sci. 23, 1-22 (2008).
42. Lonnstedt, I. & Speed, T. Replicated microarray data. Stat. Sin. 12, 31-46 (2002).
43. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267-273 (2003).
44. Zimdahl, B. et al. Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. Nature Genet. 46, 245-252 (2014).
45. Licatalosi, D. D. et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature 456, 464-469 (2008).
46. Ohyama, T. et al. Structure of Musashi1 in a complex with target RNA: The role of aromatic stacking interactions. Nucleic Acids Res. 40, 3218-3231 (2012).
47. Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene /allelespecific silencing of mutant huntingtin. Mol. Ther. 19, 2178-2185 (2011).
48. Samuel, V. T. et al. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55, 2042-2050 (2006).